SCHEMBL5258384

SCHEMBL5258384

O=C(Oc1ccc2cc[nH]c2n1)c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 9/20 0.44
MAPT P10636 8/20 0.44
MEN1 O00255 3/20 0.44
TDP1 Q9NUW8 1/20 0.44
PARP1 P09874 1/20 0.43
HSD17B10 Q99714 1/20 0.43
LMNA P02545 3/20 0.41
HDAC6 Q9UBN7 2/20 0.41
METAP2 P50579 1/20 0.41
METAP1 P53582 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
KDM4E B2RXH2 1/20 0.41
HPGD P15428 1/20 0.41
TSHR P16473 1/20 0.41
CDK8 P49336 1/20 0.39
F2 P00734 1/20 0.39
SLC6A3 Q01959 1/20 0.39
CA12 O43570 2/20 0.38
CA9 Q16790 2/20 0.38
NPC1 O15118 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12889423 0.78 BRD4 (0.38) HSD17B10LMNAKDM4EHPGDCDK8
SCHEMBL7773905 0.74 KMT2A (0.53) KMT2AMAPTMEN1TDP1LMNA
SCHEMBL29403157 0.74 KMT2A (0.53) KMT2AMAPTMEN1TDP1LMNA
SCHEMBL4345671 0.73 CNR2 (0.56) KMT2AMAPTMEN1HSD17B10HDAC6
SCHEMBL2762995 0.73 KMT2A (0.51) KMT2AMAPTMEN1TDP1LMNA
SCHEMBL30369396 0.71 NPC1 (0.60) KMT2AMAPTMEN1HDAC6NPC1
SCHEMBL4369600 0.70 LMNA (0.47) KMT2AMAPTMEN1TDP1PARP1
SCHEMBL29642309 0.69 NSD2 (0.43) LMNACDK8POLB
SCHEMBL4978551 0.69 NSD2 (0.43) LMNACDK8POLB
SCHEMBL27397397 0.69 TSHR (0.43) KMT2AMAPTMEN1TDP1PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1309590-B1 AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS PFIZER ITALIA SRL (IT) 2007-09-19 EP disclosed
US-20030004350-A1 AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS PHARMACIA & UPJOHN (IT) 2003-01-02 US disclosed
US-6486322-B1 Azaindole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA ITALIA S.P.A. (IT) 2002-11-26 US disclosed
US-6335342-B1 1H-PYRROLO(2,3-B)PYRIDINE DERIVATIVES; ANTICARCINOGENIC, ANTIMETASTASIS, ANTITUMOR AND ANTIPROLIFERATIVE AGENTS PHARMACIA & UPJOHN S.P.A. (IT) 2002-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030004350-A1 AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS FFAR4, AZI2, CNKSR1 KMT2A 1011/4885MAPT 4795/4885MEN1 3262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.